FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2754706509> ?p ?o ?g. }

• W2754706509 endingPage "116" @default.
• W2754706509 startingPage "108" @default.
• W2754706509 abstract "Cytosine arabinoside (AraC) remains the backbone of most treatment regimens for acute myeloid leukemia (AML). Incorporation of AraC into DNA activates checkpoint kinase 1 (Chk1), leading to cell-cycle arrest and diminished AraC cytotoxicity, which can be reversed by the selective Chk1 inhibitor MK-8776. Building on a Phase I trial, we conducted a phase II trial comparing timed sequential AraC with or without MK-8776.Patients with relapsed or primary refractory AML were randomized 1:1 to receive either AraC with MK-8776 (Arm A); or AraC alone (Arm B).32 patients were treated: 14 assigned to Arm A and 18 to Arm B. There were 5 (36%) complete responses (CR/CRi) and 1 (7%) partial response (PR) in Arm A, and 8 (44%) CR/CRis and 1 (6%) PR in Arm B. Median survival did not differ significantly between the two groups (5.9months in Arm A vs. 4.5 months in Arm B). MK-8776 led to a robust increase in DNA damage in circulating leukemic blasts as measured by increased γ-H2AX (16.9%±6.1% prior and 36.4%±6.8% at one hour after MK-8776 infusion, p=0.016).Response rates and survival were similar between the two groups in spite of evidence that MK-8776 augmented DNA damage in circulating leukemic blasts. Better than expected results in the control arm using timed sequential AraC and truncated patient enrollment may have limited the ability to detect clinical benefit from the combination." @default.
• W2754706509 created "2017-09-25" @default.
• W2754706509 creator A5007801126 @default.
• W2754706509 creator A5011271236 @default.
• W2754706509 creator A5012395020 @default.
• W2754706509 creator A5012591920 @default.
• W2754706509 creator A5018041025 @default.
• W2754706509 creator A5040215906 @default.
• W2754706509 creator A5040758762 @default.
• W2754706509 creator A5045588395 @default.
• W2754706509 creator A5046719320 @default.
• W2754706509 creator A5048801471 @default.
• W2754706509 creator A5054370710 @default.
• W2754706509 creator A5056464793 @default.
• W2754706509 creator A5068544225 @default.
• W2754706509 creator A5072463255 @default.
• W2754706509 creator A5085360755 @default.
• W2754706509 creator A5090468019 @default.
• W2754706509 date "2017-10-01" @default.
• W2754706509 modified "2023-10-13" @default.
• W2754706509 title "Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia" @default.
• W2754706509 cites W174683914 @default.
• W2754706509 cites W1767565691 @default.
• W2754706509 cites W1942780970 @default.
• W2754706509 cites W1969545468 @default.
• W2754706509 cites W1989819905 @default.
• W2754706509 cites W1996505651 @default.
• W2754706509 cites W2008653075 @default.
• W2754706509 cites W2011595404 @default.
• W2754706509 cites W2012677683 @default.
• W2754706509 cites W2025491043 @default.
• W2754706509 cites W2035614371 @default.
• W2754706509 cites W2036281060 @default.
• W2754706509 cites W2043402587 @default.
• W2754706509 cites W2043895957 @default.
• W2754706509 cites W2053903261 @default.
• W2754706509 cites W2055884944 @default.
• W2754706509 cites W2071088216 @default.
• W2754706509 cites W2080556827 @default.
• W2754706509 cites W2088855804 @default.
• W2754706509 cites W2093938238 @default.
• W2754706509 cites W2102815568 @default.
• W2754706509 cites W2104357345 @default.
• W2754706509 cites W2106788103 @default.
• W2754706509 cites W2114572046 @default.
• W2754706509 cites W2116858301 @default.
• W2754706509 cites W2117015521 @default.
• W2754706509 cites W2126583326 @default.
• W2754706509 cites W2133852937 @default.
• W2754706509 cites W2137013563 @default.
• W2754706509 cites W2140291353 @default.
• W2754706509 cites W2140990686 @default.
• W2754706509 cites W2141444873 @default.
• W2754706509 cites W2150480709 @default.
• W2754706509 cites W2151180466 @default.
• W2754706509 cites W2160746673 @default.
• W2754706509 cites W2161698497 @default.
• W2754706509 cites W2163112291 @default.
• W2754706509 cites W2165691162 @default.
• W2754706509 cites W2167986457 @default.
• W2754706509 cites W2171285972 @default.
• W2754706509 cites W2171883353 @default.
• W2754706509 cites W2218136981 @default.
• W2754706509 cites W2237124828 @default.
• W2754706509 cites W2255888132 @default.
• W2754706509 cites W2342670512 @default.
• W2754706509 cites W2403598312 @default.
• W2754706509 cites W2419014270 @default.
• W2754706509 cites W2467515431 @default.
• W2754706509 cites W2517650714 @default.
• W2754706509 cites W2519866904 @default.
• W2754706509 cites W326488107 @default.
• W2754706509 doi "https://doi.org/10.1016/j.leukres.2017.09.005" @default.
• W2754706509 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5639924" @default.
• W2754706509 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28957699" @default.
• W2754706509 hasPublicationYear "2017" @default.
• W2754706509 type Work @default.
• W2754706509 sameAs 2754706509 @default.
• W2754706509 citedByCount "36" @default.
• W2754706509 countsByYear W27547065092018 @default.
• W2754706509 countsByYear W27547065092019 @default.
• W2754706509 countsByYear W27547065092020 @default.
• W2754706509 countsByYear W27547065092021 @default.
• W2754706509 countsByYear W27547065092022 @default.
• W2754706509 countsByYear W27547065092023 @default.
• W2754706509 crossrefType "journal-article" @default.
• W2754706509 hasAuthorship W2754706509A5007801126 @default.
• W2754706509 hasAuthorship W2754706509A5011271236 @default.
• W2754706509 hasAuthorship W2754706509A5012395020 @default.
• W2754706509 hasAuthorship W2754706509A5012591920 @default.
• W2754706509 hasAuthorship W2754706509A5018041025 @default.
• W2754706509 hasAuthorship W2754706509A5040215906 @default.
• W2754706509 hasAuthorship W2754706509A5040758762 @default.
• W2754706509 hasAuthorship W2754706509A5045588395 @default.
• W2754706509 hasAuthorship W2754706509A5046719320 @default.
• W2754706509 hasAuthorship W2754706509A5048801471 @default.
• W2754706509 hasAuthorship W2754706509A5054370710 @default.
• W2754706509 hasAuthorship W2754706509A5056464793 @default.

• next